📊 Backtest📒 Journal Updated 22/07/2026
← 🔥 Turbo
📐 Simulate Position
FRESHReport written today · at $1.29

BIVI

ค่าขนมSMALL CAP
BioVie Inc. · NASDAQ · Healthcare / Biotechnology (Neurology)
$1.29
▼ 9.47%
MCap $9.7M
Self-fetched today (no live-prices.json cache yet). Down 9.47% Jul 21, near the 52-week low ($1.06) and down ~85% from the 52-week high ($8.84) — the market is pricing in real doubt ahead of two Phase 2 readouts rather than anticipating a win.
BusinessClinical-stage neuro biotech · bezisterim (NE3107) in Phase 2 for Long COVID (ADDRESS-LC) and Parkinson's (SUNRISE-PD) · nano-cap trading near its 52-week low into two binary readouts
Thesis

BioVie has two binary Phase 2 readouts converging in the same window: SUNRISE-PD (Parkinson's) already completed, and ADDRESS-LC (Long COVID) topline data anticipated late summer 2026 after full enrollment in May. Four analysts average a $5.75 target (+346% from here) — real, broad-consensus upside, not a single outlier. The catch: BioVie has explicitly disclosed substantial doubt about its ability to continue as a going concern, with roughly $20-25M cash against a burn rate near $11M per half-year, and a $300M shelf registration on file that could dilute hard if a raise is needed before data reads out. ⚠️ SURVIVAL: this is a real risk, not boilerplate — a delayed or negative readout combined with a forced dilutive raise is a genuine path to a much lower stock, not just a paper loss. Included here specifically because the binary catalyst (data, not financing) is what will move the stock first, and the upside asymmetry is real and analyst-backed, not constructed. Max 2-3% position size only.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

ค่าขนม — tiny position only, sized for total loss. Real binary upside from two Phase 2 readouts in the same window, but the going-concern disclosure means dilution or failure can both end the thesis independent of each other.

78
score / 100 ⓘ
⚡ Catalyst
🧠 ADDRESS-LC Phase 2 Topline (Long COVID)LATE SUMMER 2026

Topline results for bezisterim in Long COVID neurological symptoms, following full trial enrollment announced May 26, 2026. A positive readout on this indication plus the completed Parkinson's data would give BioVie two shots on goal in the same catalyst window.

Late Summer 2026
🧬 SUNRISE-PD Phase 2 (Parkinson's Disease)NEAR-TERM

Bezisterim's early-stage Parkinson's disease trial has completed — full data readout and analysis expected around the same window as ADDRESS-LC, giving investors two binary neurology catalysts to trade off the same drug.

H2 2026
🎯 Entry Point
Entry 1
$1.29
Current price — near the 52-week low, thesis is entirely pre-dataScale in (small)
Entry 2PREFERRED
$1.1–1.2
Near the 52-week low ($1.06) — best R/R if weakness continues into the data windowIf dips
Entry 3
$0.85
Deep capitulation — only on a financing scare or broad biotech selloff, still ahead of dataDeep dip only
✅ Take Profit
TP1
Base — mixed/inconclusive data, market gives partial credit
$2.32
+80%
TP2
Bull — one of the two readouts (ADDRESS-LC or SUNRISE-PD) is clearly positive
$3.87
+200%
TP3 🌙
Moon — both readouts positive, hits full analyst consensus target
$5.75
+346%
🔴 Stop Loss
Tight Stop
Below the 52-week low — thesis-neutral pre-data but a real warning sign
$1
-22.5%
Hard Stop
Risk-of-zero territory — a going-concern financing crisis or a clearly negative readout
$0.7
-45.7%
Risk / Reward
From Entry 2 ($1.15 mid) tight stop vs TP2
8.9 : 1
⚠ Asymmetric ✅ but this is a going-concern nano-cap — 2-3% max position, no exceptions
📅 Estimate Date
ADDRESS-LC Topline (Long COVID)
Binary readout — the primary near-term catalyst
Late Summer 2026
Positive/negative on primary endpoint
SUNRISE-PD Data (Parkinson's)
Trial completed, data analysis underway
H2 2026
Second binary shot in the same window
📈 Possible Up % — Scenario Spread
Bear
-60%
$0.52
Base
+80%
$2.32
Bull
+200%
$3.87
Moon
+346%
$5.75
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed holds at 3.50–3.75%, but new Chair Warsh's hawkish tone has 9 of 18 officials projecting a further 2026 hike, with the next FOMC decision Jul 28–29, 2026.
Inflation
Core inflation remains above target and the 10-year yield sits near 4.48% — a real headwind for a going-concern nano-cap that will likely need to raise capital regardless of the data outcome.
Sector Impact
Binary FDA/clinical-data catalysts are largely macro-independent in direction, but the survival risk here is directly worsened by a high-rate environment that makes any dilutive raise more expensive and more dilutive.
Summary
MEDIUM for the catalyst itself, HIGH for the financing risk — a hawkish Jul 28-29 FOMC wouldn't change whether the Phase 2 data reads out positive or negative, but it would make a forced capital raise (a real possibility given the going-concern disclosure) more punishing for existing shareholders.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (4 analysts)
Buy$5.75+346%
High-end estimate
Buy$6.75+423%
current price $1.29
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

FPRX✅ Goodhistorical
+349%
in 1 day
Five Prime Therapeutics — positive mid-stage combination cancer therapy data
Closest same-genre precedent for a small-cap binary Phase 2 win driving an outsized single-day move — directly relevant to BIVI's ADDRESS-LC/SUNRISE-PD setup.
BIVI❌ Bad2026
-85%
in 180 days
Stock decline from 52-week high to current level amid going-concern disclosure
Same-company precedent for the downside — shows how far this stock can fall on financing/sentiment risk even before a clear negative data readout.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-22% / -45%) only when trading the earnings spot — not for the core holding (use the -22.5% / -45.7% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
0% to +10% pre-event drift, occasionally down into the eventminimal pre-event runup; the move happens on the data itself

Clinical-stage nano-caps with binary Phase 2 data typically see limited pre-readout runup and instead trade sideways-to-down into the event as uncertainty peaks, then move sharply on the actual data — consistent with BIVI's current position near its 52-week low heading into the readout window.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +150%
range: +50% to +349%· historical small-cap Phase 2 precedent
Small-cap biotechs on positive mid-stage cancer/neuro data have posted moves in this range — Five Prime Therapeutics jumped as much as 349% on positive mid-stage combination-therapy data as the closest same-genre precedent for a nano-cap binary Phase 2 win.
❌ Catalyst Missavg -50%
range: -30% to -70%· general small-cap biotech pattern
Nano-cap biotechs with going-concern disclosures typically see 30-70%+ drawdowns on a negative or ambiguous Phase 2 readout, compounded by the near-certain forced dilutive raise that follows — BIVI's own 85% decline from its 52-week high already shows this stock's downside sensitivity to negative sentiment.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio

Going-concern nano-cap with two binary catalysts and real risk of zero — 2% caps the loss to a tolerable level while keeping meaningful exposure to the 346% consensus upside if either readout hits.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-22%($1)
Below the 52-week low ahead of data — thesis-neutral but a real warning sign of financing stress
After Catalyst (Bad Result)-45%
A clearly negative readout on both trials, or a forced dilutive raise at a much lower price, ends the thesis — exit
📎 Sources

Generated 2026-07-22 · Not financial advice